ConductScience.org, home

Trial · NCT00836472

Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting

NCT00836472, Phase 1, Completed, Teva Pharmaceuticals USA; results first posted 2009-08-04

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting. Trials, record NCT00836472. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00836472

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting
NCT number
NCT00836472
Status
Completed
Phases
Phase 1
Enrollment
60 participants, actual
Lead sponsor
Teva Pharmaceuticals USA
Conditions
Healthy
Interventions
Glyburide/Metformin 5 mg/500 mg Tablets, Glucovance® 5 mg/500 mg Tablets
First posted
2009-02-04
Last updated
2024-08-19
Results first posted
2009-08-04

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryCmax (Maximum Observed Concentration) - GlyburideBlood samples collected over 36 hour periodBioequivalence based on Cmax
PrimaryAUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - GlyburideBlood samples collected over 36 hour periodBioequivalence based on AUC0-inf
PrimaryAUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - GlyburideBlood samples collected over 36 hour periodBioequivalence based on AUC0-t
PrimaryCmax (Maximum Observed Concentration) - MetforminBlood samples collected over 36 hour periodBioequivalence based on Cmax
PrimaryAUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - MetforminBlood samples collected over 36 hour periodBioequivalence based on AUC0-inf
PrimaryAUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - MetforminBlood samples collected over 36 hour periodBioequivalence based on AUC0-t

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYCmax (Maximum Observed Concentration) - GlyburideBlood samples collected over 36 hour periodData from all subjects who completed the study were included in the statistical analysis.ng/mLMEAN
PRIMARYAUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - GlyburideBlood samples collected over 36 hour periodData from all subjects who completed the study were included in the statistical analysis.ng*h/mLMEAN
PRIMARYAUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - GlyburideBlood samples collected over 36 hour periodData from all subjects who completed the study were included in the statistical analysis.ng*h/mLMEAN
PRIMARYCmax (Maximum Observed Concentration) - MetforminBlood samples collected over 36 hour periodData from all subjects who completed the study were included in the statistical analysis.ng/mLMEAN
PRIMARYAUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - MetforminBlood samples collected over 36 hour periodData from all subjects who completed the study were included in the statistical analysis.ng*h/mLMEAN
PRIMARYAUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - MetforminBlood samples collected over 36 hour periodData from all subjects who completed the study were included in the statistical analysis.ng*h/mLMEAN

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Cmax (Maximum Observed Concentration) - GlyburideGlyburide Metformin106.46Standard Deviation 34.86ng/mL
Cmax (Maximum Observed Concentration) - GlyburideGlucovance®116.53Standard Deviation 52.35ng/mL
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - GlyburideGlyburide Metformin805.92Standard Deviation 28813ng*h/mL
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - GlyburideGlucovance®806.89Standard Deviation 256.14ng*h/mL
AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - GlyburideGlyburide Metformin773.84Standard Deviation 276.56ng*h/mL
AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - GlyburideGlucovance®781.35Standard Deviation 255.31ng*h/mL
Cmax (Maximum Observed Concentration) - MetforminGlyburide Metformin840.23Standard Deviation 249.06ng/mL
Cmax (Maximum Observed Concentration) - MetforminGlucovance®889.45Standard Deviation 253.56ng/mL
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - MetforminGlyburide Metformin5915.32Standard Deviation 1663.04ng*h/mL
AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - MetforminGlucovance®6047.23Standard Deviation 1353.17ng*h/mL

Participant flow18

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
First InterventionSTARTEDGlyburide Metformin (Test) First30
First InterventionSTARTEDGlucovance® (Reference) First30
First InterventionCOMPLETEDGlyburide Metformin (Test) First30
First InterventionCOMPLETEDGlucovance® (Reference) First30
First InterventionNOT COMPLETEDGlyburide Metformin (Test) First0
First InterventionNOT COMPLETEDGlucovance® (Reference) First0
WashoutSTARTEDGlyburide Metformin (Test) First30
WashoutSTARTEDGlucovance® (Reference) First30
WashoutCOMPLETEDGlyburide Metformin (Test) First28
WashoutCOMPLETEDGlucovance® (Reference) First27

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00836472

GET https://conductscience.org/api/trials/v1/NCT00836472/registered